Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Change in Receivables (2020 - 2025)

LifeStance Health (LFST) has disclosed Change in Receivables for 6 consecutive years, with -$25.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 3.78% to -$25.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$36.1 million, a 664.2% decrease, with the full-year FY2025 number at -$36.1 million, down 664.2% from a year prior.
  • Change in Receivables was -$25.4 million for Q4 2025 at LifeStance Health, down from -$8.4 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $50.5 million in Q1 2024 to a low of -$26.4 million in Q4 2024.
  • A 5-year average of $1.3 million and a median of $3.3 million in 2021 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 481.55% in 2022; the steepest drop was 469.59% in 2022.
  • LifeStance Health's Change in Receivables stood at $3.5 million in 2021, then tumbled by 469.59% to -$12.9 million in 2022, then tumbled by 87.82% to -$24.3 million in 2023, then decreased by 8.44% to -$26.4 million in 2024, then grew by 3.78% to -$25.4 million in 2025.
  • Per Business Quant, the three most recent readings for LFST's Change in Receivables are -$25.4 million (Q4 2025), -$8.4 million (Q3 2025), and -$10.9 million (Q2 2025).